Keros Therapeutics: Diverging Signals Create Investor Crossroads

Keros Therapeutics (KROS) finds itself at the center of conflicting market narratives this Friday, presenting investors with a complex puzzle. The biotechnology firm is simultaneously the subject of conservative price targeting from Bank of America and top-tier value stock recognition from quantitative analysts.

The institutional landscape for Keros Therapeutics showed notable division during the third quarter of 2025. While 90 investment firms reduced their holdings, 85 institutions chose to increase their exposure to the biotech company.

Key institutional movements included:
* Goldman Sachs expanded its position by 441,923 shares, representing a 50.0% increase
* Logos Global Management substantially reduced its stake by 1.15 million shares, a 57.5% decrease
* Morgan Stanley Read more...